TELA Bio, Inc.
TELA Bio, Inc. develops and commercializes biologic and synthetic surgical implant products used to reinforce soft tissue in hernia repair and plastic/reconstructive surgery. The company sells primarily in the United States through a direct sales force, with additional commercial activity in parts of Europe.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaReinforced tissue matrix products used in hernia and soft-tissue repair procedures.
Reinforced tissue matrix products used in plastic and reconstructive surgery.
A configuration of the OviTex platform used in specific hernia repair applications.
Complementary surgical and wound-care related products distributed through partnerships.
Asiakkaat
TELA Bio sells mainly to hospital accounts, where surgeons and purchasing teams decide which implant products are stocked and used in procedures. Its products are also accessed through consignment arrangements, group purchasing organizations, and integrated delivery networks that influence hospital adoption and purchasing access.
Primary buyers that purchase OviTex and OviTex PRS for use in surgical procedures and inventory stocking.
Clinical users who select the products for hernia, plastic, and reconstructive surgery.
Contracting intermediaries that improve access to hospital accounts and standardize purchasing.
Health-system buyers that can broaden access across multiple hospitals and facilities.
Smaller non-U.S. customers reached through sales representatives, contractors, and distributors.
Strategia
TELA Bio is focused on expanding adoption of its OviTex platform by increasing hospital penetration, broadening procedure use within existing accounts, and improving sales-force productivity. It is also investing in product variations, longer shelf-life packaging, and lower-cost resorbable polymer-based devices to extend the platform and support future indications.
More procedures per account can raise utilization without relying only on new customer wins.
Contract coverage can improve hospital access and reduce friction in purchasing decisions.
New configurations and enhancements can extend the product line and support broader clinical use.
Adjacent technologies can diversify revenue sources and reduce dependence on a single product family.
Maantiede
Q1/2026TELA Bio generates the vast majority of its revenue in the United States, where it maintains a direct sales force and the largest installed commercial footprint. It also has a smaller commercial presence in the United Kingdom and European Union, which broadens its addressable market but remains secondary to the U.S. business.
Riskit
TELA Bio depends heavily on hospital adoption of a limited product family, so slower procedure growth or weaker purchasing conversion can affect revenue momentum. The business also faces execution risk from reimbursement, competitive surgical implant markets, inventory management, and reliance on third-party manufacturing and licensing arrangements.
Most revenue has come from a small number of reinforced tissue matrix products, so demand weakness would have an outsized effect.
Kohdistuu: OviTex and OviTex PRS
Sales depend on surgeon preference, hospital contracting, and stocking decisions that can take time to convert.
Kohdistuu: U.S. hospital accounts
OviTex products are sourced under a license arrangement with Aroa, creating reliance on third-party economics and terms.
Kohdistuu: Aroa license and transfer-cost structure
Debt maturities and interest obligations can constrain capital allocation and increase sensitivity to operating performance.
Kohdistuu: Credit facilities
Lower elective procedure activity or tighter hospital budgets can slow utilization and new account growth.
Kohdistuu: Surgical procedure demand
If volume growth lags, the company may need to record additional excess and obsolete inventory charges.
Kohdistuu: Finished goods and consignment inventory
Kirjanpito
Harkinnanvaraiset erätDifferent contract terms change when revenue is recorded and can affect quarterly comparability.
Vaikutus: Point-in-time recognition with consignment exceptions
Products held at hospitals remain on the balance sheet until used, affecting working capital and revenue timing.
Vaikutus: Inventory and revenue timing
Slower sales growth can require write-downs that reduce reported gross margin and earnings.
Vaikutus: Cost of revenue and inventory valuation
The fixed transfer-cost structure and true-up mechanics directly affect product cost economics.
Vaikutus: Cost of revenue
Amortization of deferred financing costs and exit fees can materially affect reported net loss.
Vaikutus: Interest expense and non-cash charges
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Integra LifeSciences Holdings Corporation
IART · Surgical & Medical Instruments & Apparatus
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
KALA BIO, Inc
KALA · Pharmaceutical Preparations
Teleflex Incorporated
TFX · Surgical & Medical Instruments & Apparatus
Sanara MedTech Inc.
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
Päivitetty: 24.9.2026